Ann: Letter to Shareholders , page-5

reading between the lines, you can sense a smile beginning to appear on mgmt's face. with safety over the line, you get the sense there is a fair degree of confidence that the in vitro work will replicate itself and the efficacy target will be achieved. that is what i suspect. i will go in for the SPP as they are confident enough their HIV science is on the right path - which it clearly seems to be if recent literature is anything to go by.

big question is 5, 10 or 15K... i suspect 3.5M will keep them going for 12-18 months? perhaps that is irrelevant if they strike a nice deal in the interim.